Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENABLE-Hip trial of abbreviated rivaroxaban prophylaxis after primary hip arthroplasty
2023-507490-18-00Phase 3Authorised
- Sponsor
- University Medical Center Mainz
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in venous thromboembolism (VTE) comparing Rivaroxaban with Placebo (2 arms). Planned start Nov 2024; status: authorised.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2023-507490-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507490-18-00.